Discontinue administration if a systemic hypersensitivity reaction (immediate or delayed) occurs. Rotate inj site w/ each inj. Do not inj into tender, damaged, bruised or scarred skin. Patients treated w/ lebrikizumab who develop conjunctivitis that does not resolve following standard treatment should undergo ophthalmological exam. Treat patients w/ pre-existing helminth infections before initiating lebrikizumab treatment. Discontinue lebrikizumab treatment if patients become infected while receiving lebrikizumab & do not respond to antihelminth treatment. Safety & efficacy of concurrent use w/ live & live attenuated vaccines have not been established. Avoid use during pregnancy. Discontinue breast-feeding or discontinue lebrikizumab therapy. Safety & efficacy in childn aged 6 mth to <12 yr or adolescents 12-17 yr & weighing <40 kg have not yet been established.
Sign Out
